RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Total assets

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndTotal assets (Million USD)YoY (%)
Dec 31, 202437,759+14.15%
Dec 31, 202333,080+13.23%
Dec 31, 202229,215+14.86%
Dec 31, 202125,435+48.19%
Dec 31, 202017,163+15.93%
Dec 31, 201914,805+26.17%
Dec 31, 201811,735+33.89%
Dec 31, 20178,764+25.68%
Dec 31, 20166,973+24.32%
Dec 31, 20155,609+44.87%
Dec 31, 20143,872+31.20%
Dec 31, 20132,951+41.84%
Dec 31, 20122,080+57.19%
Dec 31, 20111,324+21.49%
Dec 31, 20101,089

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)